Also trades as: 0IGA.L (LSE) · $vol 0M
EBS NYSE
Emergent BioSolutions Inc.
1W: -0.3%
1M: -6.6%
3M: -13.3%
YTD: -49.3%
1Y: -34.4%
3Y: +185.6%
5Y: -87.4%
$6.67
+0.33 (+5.21%)
After Hours: $6.45 (-0.22, -3.30%)
Weekly Expected Move ±10.7%
$5
$6
$6
$7
$8
Credit Risk of going bust: higher than 91% of companies Debt: 64.2% of company value Bonds: $63.5M held by 75 funds, 397 bp over Treasuries → details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.11 (down 82%), Emergent BioSolutions Inc. would be worth roughly what it owes.
Total debt $581.8M against a stock market value of $325.1M.
Distance to default 1.48 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $290.9M (short-term plus half of long-term), stock volatility 81.0%; Altman Z 0.83. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.11 (down 82%), Emergent BioSolutions Inc. would be worth roughly what it owes.
Total debt $581.8M against a stock market value of $325.1M.
Distance to default 1.48 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $290.9M (short-term plus half of long-term), stock volatility 81.0%; Altman Z 0.83. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (52)
Swedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue Estimates
Emergent BioSolutions CFO Richard Lindahl to retire, Frank Vargo named interim CFO
Novavax, Moderna cool as WHO downplays plague-related death in Russia
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Bank of America Corp DE Acquires New Shares in Emergent Biosolutions Inc. $EBS
Emergent BioSolutions restructuring includes 90 job cuts
Bank of New York Mellon Corp Acquires Shares of 219,661 Emergent Biosolutions Inc. $EBS
BlackRock Inc. Invests $39.52 Million in Emergent Biosolutions Inc. $EBS
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Catalyst Watch: Eyes on Walmart, Alibaba, Reddit, and McDonald's energy drink push
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Connecticut's first case of clade I mpox + ANDV virus
Emergent (EBS) Q1 2026 Earnings Transcript
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
12 Health Care Stocks Moving In Thursday's After-Market Session
Emergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
Earnings Scheduled For April 30, 2026
Emergent Biosolutions Q1 2026 Earnings Preview
Emergent BioSolutions signs multi-year manufacturing deal with SAB Biotherapeutics worth about $50M
Emergent BioSolutions signs $34.5M vaccine manufacturing, distribution deal
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent (EBS) Q4 2025 Earnings Transcript
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
Emergent BioSolutions secures $60M contracts
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
Emergent Biosolutions Inc. $EBS Shares Purchased by American Century Companies Inc.
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)
Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results
Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent Biosolutions Non-GAAP EPS of -$0.43 misses by $0.54, revenue of $148.7M misses by $68.8M
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading
Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site